swissnex Boston invites you to a talk with Professor Omid Farokhzad on current efforts in the design and optimization of polymeric nanoparticles for medical applications. “The annual worldwide market of controlled release polymer systems which extends beyond drug delivery is now estimated at $100 billion and these systems are used by over 100 million people each year.” The reception will be hosted by Debiopharm Group, and followed by a reception serving refreshments, hors d’oeurvres and Swiss wine.
About Omid Farokhzad
Omid Farokhzad is an Associate Professor at Harvard Medical School (HMS) and a physician-scientist at Brigham and Women’s Hospital (BWH). Dr. Farokhzad directs the Laboratory of Nanomedicine and Biomaterials at BWH. He is a faculty member of the Brigham Research Institute Cancer Research Center and a member of the Dana Farber/Harvard Cancer Center. Farokhzad’s research is focused on the development of therapeutic nano particle technologies.
Dr. Farokhzad has authored approximately 110 papers and holds more than 125 issued/pending US and International patents. His technologies formed the foundational platform for the launch of three biotechnology companies: BIND Therapeutics (NASDAQ: BIND), Selecta Biosciences, and Blend Therapeutics, which are translating cutting edge academic innovations toward commercialization and societal impact.